The challenge now is to take the tremendous promise of the ACT Accelerator and COVAX to scale, said and explained that almost 200 vaccines for COVID19 are currently in clinical and pre-clinical testing. The history of vaccine development tells us that some will fail, and some will succeed, WHO said.
By B N KUMAR
MUMBAI, Sep 21 (BNC Network) Admitting that there is no guarantee that any single vaccine now in development will work, the World Health Organisation said it is facing “some daunting challenges” as far as funding for the development of COVAX is concerned.
The WHO immediately needs 15 billion dollars for the ACT Accelerator to work as planned.
ACT stands for The Access to COVID-19 Tools and WHO said three billion dollars have been invested so far.
"Our estimates suggest that once an effective #COVID19 vaccine has been distributed, and international travel and trade is fully restored, the economic gains will far outweigh the $38 billion investment required for the ACT Accelerator," said WHO Director General Dr Tedros Adhanom Ghebreyesus.
Addressing the global media during a virtual media conference Dr Tedros said “We are at a critical point and we need a significant increase in countries’ political and financial commitment".
"The overarching goal of the COVAX Facility is to ensure that all countries have access to vaccines at the same time, and that priority is given to those most at risk, including health workers, older people and others at the highest risk," Dr Tedros said.
The more candidates we test, the higher the chance we will have a safe and efficacious vaccine, he said and told the world nations: We must move heaven & earth to ensure equitable access to diagnostics, therapeutics and vaccines.”
We continue to call on all countries to use every tool at their disposal to suppress #COVID19 transmission & save lives, until & after we have a vaccine"
The challenge now is to take the tremendous promise of the ACT Accelerator and COVAX to scale, said and explained that almost 200 vaccines for COVID19 are currently in clinical and pre-clinical testing. “The history of vaccine development tells us that some will fail, and some will succeed"